Related Experiment Video
Updated: Jun 6, 2025
09:18
Measurements of Motor Function and Other Clinical Outcome Parameters in Ambulant Children with Duchenne Muscular Dystrophy
Published on: January 12, 2019
10.3K
A computational tool to optimize clinical trial parameter selection in Duchenne muscular dystrophy: A practical guide
Jordan Wilk1,2, Varun Aggarwal3, Mike Pauley3
1Department of Pharmaceutics, Center for Pharmacometrics and Systems Pharmacology, College of Pharmacy, University of Florida, Orlando, Florida, USA.
CPT: Pharmacometrics & Systems Pharmacology
|November 27, 2024
Summary
A new clinical trial simulator (CTS) aids Duchenne muscular dystrophy (DMD) research by optimizing trial design. This tool helps researchers create more efficient and effective trials for this rare pediatric disease.
Area of Science:
- Neurology
- Clinical Trial Design
- Biostatistics
Background:
- Duchenne muscular dystrophy (DMD) presents significant clinical trial design challenges due to patient scarcity and disease heterogeneity.
- Existing disease progression models capture longitudinal changes in functional tests, forced vital capacity, and ambulatory assessment scores.
Observation:
- A quantitative clinical trial simulator (CTS) has been developed, integrating five established disease progression models.
- The CTS allows for the optimization of various trial parameters for DMD studies.
Findings:
- The model-based CTS facilitates the optimization of trial designs for five common DMD efficacy endpoints.
- Case studies demonstrate the tool's utility in optimizing trial parameters without compromising statistical significance.
Implications:
- This simulator can help mitigate risks associated with trial length, size, and participant selection criteria.
- The CTS provides a guide for researchers to design more efficient and effective DMD clinical trials.
